Rigel Pharmaceuticals (RIGL) Capital Expenditures (2010 - 2023)

Rigel Pharmaceuticals' Capital Expenditures history runs 14 years deep, the most recent figure standing at $29000.0 for Q4 2023.

• On a quarterly basis, Capital Expenditures fell 96.91% year-over-year to $29000.0 in Q4 2023; TTM through Dec 2023 was -$56000.0, a 112.44% decrease from a year earlier, with the FY2023 full-year figure at -$56000.0, down 112.44% from the prior year.
• Capital Expenditures improved to $29000.0 in Q4 2023 per RIGL's latest filing, from $14000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.5 million in Q4 2019 and bottomed at -$678000.0 in Q3 2022.
• The 5-year median for Capital Expenditures is $6500.0 (2023), against an average of $163050.0.
• Biggest YoY gain for Capital Expenditures was 10216.67% in 2020; the steepest drop was 3962.5% in 2020.
• Year by year, Capital Expenditures stood at $1.5 million in 2019, then retreated by 23.88% to $1.1 million in 2020, then plunged by 143.76% to -$498000.0 in 2021, then surged by 288.76% to $940000.0 in 2022, then plunged by 96.91% to $29000.0 in 2023.
• Per Business Quant, the three latest RIGL Capital Expenditures figures stand at $29000.0 (Q4 2023), $14000.0 (Q3 2023), and -$1000.0 (Q2 2023).